Advertisement
Screener

Corvus Pharmaceuticals, Inc. (CRVS) ROA

Corvus Pharmaceuticals, Inc. ROA

Return on assets (ROA) is the profit a company earns for every dollar of assets it uses, shown as a percentage. It is net income divided by total assets, and the table shows both amounts. Because assets are funded by lenders as well as shareholders, ROA is not inflated by borrowing the way ROE can be, and it is naturally lower for businesses that need many factories, stores or other assets. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Corvus Pharmaceuticals, Inc. roa for the quarter ending 2026-06-30 was -22.62%, a change of 27.83% year-over-year.
  • Corvus Pharmaceuticals, Inc. roa for the quarter ending 2026-03-31 was -17.44%, a change of 52.21% year-over-year.
  • Corvus Pharmaceuticals, Inc. roa for the quarter ending 2025-12-31 was -21.49%, a change of 68.91% year-over-year.
  • Corvus Pharmaceuticals, Inc. roa for the quarter ending 2025-09-30 was -18.73%, a change of 77.90% year-over-year.
  • Corvus Pharmaceuticals, Inc. roa for fiscal 2025 was -21.49%, a change of 68.91% from fiscal 2024.
  • Corvus Pharmaceuticals, Inc. roa for fiscal 2024 was -90.40%, a change of -31.07% from fiscal 2023.
  • Corvus Pharmaceuticals, Inc. roa for fiscal 2023 was -59.34%, a change of 1.20% from fiscal 2022.
  • Corvus Pharmaceuticals, Inc. roa for fiscal 2022 was -60.53%, a change of -21.03% from fiscal 2021.
Available history
2015-12-31 to 2026-06-30
Data captured

Historical ROA

DateROANet income 12 monthNet income 3 monthTotal assets
2026-06-30-22.62%-$54.13M-$17.96M$239.27M
2026-03-31-17.44%-$44.17M-$13.69M$253.2M
2025-12-31-21.49%-$15.28M-$12.34M$71.12M
2025-09-30-18.73%-$15.08M-$10.16M$80.47M
2025-06-30-50.45%-$45.14M-$8.00M$89.46M
2025-03-31-69.65%-$41.4M$15.19M$59.44M
2024-12-31-90.40%-$62.29M-$12.12M$68.91M
2024-09-30-96.63%-$56.83M-$40.22M$58.82M
2024-06-30-35.03%-$22.62M-$4.26M$64.56M
2024-03-31-62.01%-$24.86M-$5.70M$40.08M
2023-12-31-59.34%-$27.03M-$6.62M$45.55M
2023-09-30-58.13%-$30.19M-$6.00M$51.94M
2023-06-30-67.23%-$39.02M-$6.50M$58.04M
2023-03-31-70.25%-$40.88M-$7.87M$58.2M
2022-12-31-60.53%-$41.31M-$9.82M$68.24M
2022-09-30-50.69%-$40.73M-$14.83M$80.35M
2022-06-30-39.52%-$36.57M-$8.36M$92.54M
2022-03-31-39.45%-$39.96M-$8.30M$101.29M
2021-12-31-39.51%-$43.24M-$9.24M$109.46M
2021-09-30-5.58%-$6.66M-$10.67M$119.32M
2021-06-30-5.28%-$5.78M-$11.75M$109.39M
2021-03-31-4.25%-$4.64M-$11.58M$109.24M
2020-12-31-7.01%-$6M$27.35M$85.53M
2020-09-30-79.46%-$44.39M-$9.80M$55.86M
2020-06-30-71.05%-$45.6M-$10.61M$64.18M
2020-03-31-64.99%-$47.96M-$12.94M$73.8M
2019-12-31-55.80%-$46.67M-$11.05M$83.65M
2019-09-30-49.89%-$46.13M-$11.00M$92.47M
2019-06-30-44.25%-$45.63M-$12.98M$103.12M
2019-03-31-39.43%-$44.28M-$11.64M$112.31M
2018-12-31-39.70%-$46.94M-$10.51M$118.23M
2018-09-30-38.01%-$48.36M-$10.50M$127.22M
2018-06-30-36.67%-$50.58M-$11.63M$137.92M
2018-03-31-36.27%-$53.93M-$14.30M$148.69M
2017-12-31-58.73%-$55.66M-$11.93M$94.78M
2017-09-30-52.32%-$54.82M-$12.72M$104.79M
2017-06-30-45.37%-$52.4M-$14.98M$115.49M
2017-03-31-36.24%-$46.06M-$16.04M$127.1M
2016-12-31-25.95%-$36.38M-$11.09M$140.15M
2016-09-30-20.92%-$31.33M-$10.30M$149.76M
2016-06-30-15.41%-$24.18M-$8.64M$156.92M
2016-03-31-22.75%-$35.77M-$6.35M$157.22M
2015-12-31-31.83%-$31.34M-$6.04M$98.46M

Annual ROA

DateROANet income 12 monthTotal assets
2025-12-31-21.49%-$15.28M$71.12M
2024-12-31-90.40%-$62.29M$68.91M
2023-12-31-59.34%-$27.03M$45.55M
2022-12-31-60.53%-$41.31M$68.24M
2021-12-31-39.51%-$43.24M$109.46M
2020-12-31-7.01%-$6M$85.53M
2019-12-31-55.80%-$46.67M$83.65M
2018-12-31-39.70%-$46.94M$118.23M
2017-12-31-58.73%-$55.66M$94.78M
2016-12-31-25.95%-$36.38M$140.15M
2015-12-31-31.83%-$31.34M$98.46M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
Pacira BioSciences, Inc. (PCRX)United States$1.020B69.03
Kura Oncology, Inc. (KURA)United States$0.967B-3.29
Arbutus Biopharma Corp (ABUS)$0.965B6.19
MoonLake Immunotherapeutics (MLTX)Switzerland$1.031B-5.43
Savara Inc (SVRA)United States$1.044B-9.10
Jade Biosciences, Inc. (JBIO)United States$0.936B-9.21
MANNKIND CORP (MNKD)United States$1.058B-30.41
Alto Neuroscience, Inc. (ANRO)United States$1.065B-11.02
Apnimed, Inc. (APMD)United States$0.899B